Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.
Palumbo A et al. J Clin Oncol. 2015 Aug 17. pii: JCO.2014.60.2466. [Epub ahead of print].

Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myelomapatients aged 65 years or older: a retrospective single Institutional analysis.
Minoia C et al. Bone Marrow Transplant. 2015 Aug 17. doi: 10.1038/bmt.2015.185. [Epub ahead of print].

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.
Uy GL et al. Bone Marrow Transplant. 2015 Aug 24. doi: 10.1038/bmt.2015.190. [Epub ahead of print].

Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib induced neurotoxicity.
Mueller BU et al. Leuk Lymphoma. 2015 Aug 21:1-28. [Epub ahead of print].

Phase I dose-escalation study of cyclophosphamide combined with bortezomib and dexamethasone in Japanese patients with relapsed and/or refractory multiple myeloma.
Sugiura I et al. Int J Hematol. 2015 Aug 23. [Epub ahead of print].

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
Matsue K et al. Cancer Sci. 2015 Aug 20. doi: 10.1111/cas.12772. [Epub ahead of print].

Cytogenetics and long-term survival of pomalidomide and low-dose dexamethasone in refractory or relapsed and refractory multiple myeloma.
Dimopoulos MA et al. Haematologica. 2015 Aug 6. pii: haematol.2014.117077. [Epub ahead of print].

Salvage therapy with bortezomib and dexamethasone in elderly patients with relapsed/refractory multiple myeloma.
Castelli R et al. Anticancer Drugs. 2015 Aug 20. [Epub ahead of print].